AIDS Research and Therapy (May 2017)
Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings
- Sasisopin Kiertiburanakul,
- David Boettiger,
- Oon Tek Ng,
- Nguyen Van Kinh,
- Tuti Parwati Merati,
- Anchalee Avihingsanon,
- Wing-Wai Wong,
- Man Po Lee,
- Romanee Chaiwarith,
- Adeeba Kamarulzaman,
- Pacharee Kantipong,
- Fujie Zhang,
- Jun Yong Choi,
- Nagalingeswaran Kumarasamy,
- Rossana Ditangco,
- Do Duy Cuong,
- Shinichi Oka,
- Benedict Lim Heng Sim,
- Winai Ratanasuwan,
- Penh Sun Ly,
- Evy Yunihastuti,
- Sanjay Pujari,
- Jeremy L. Ross,
- Matthew Law,
- Somnuek Sungkanuparph,
- on behalf of the TREAT Asia HIV Observational Databases (TAHOD)
Affiliations
- Sasisopin Kiertiburanakul
- Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University
- David Boettiger
- The Kirby Institute, University of New South Wales
- Oon Tek Ng
- Tan Tock Seng Hospital
- Nguyen Van Kinh
- National Hospital of Tropical Diseases
- Tuti Parwati Merati
- Department of Medicine, Faculty of Medicine, Udayana University & Sanglah Hospital
- Anchalee Avihingsanon
- HIV-NAT/Thai Red Cross AIDS Research Centre
- Wing-Wai Wong
- Taipei Veterans General Hospital
- Man Po Lee
- Queen Elizabeth Hospital
- Romanee Chaiwarith
- Research Institute for Health Sciences
- Adeeba Kamarulzaman
- University Malaya Medical Centre
- Pacharee Kantipong
- Chiangrai Prachanukroh Hospital
- Fujie Zhang
- Beijing Ditan Hospital, Capital Medical University
- Jun Yong Choi
- Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine
- Nagalingeswaran Kumarasamy
- Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), YRGCARE Medical Centre, VHS
- Rossana Ditangco
- Research Institute for Tropical Medicine
- Do Duy Cuong
- Bach Mai Hospital
- Shinichi Oka
- National Center for Global Health and Medicine
- Benedict Lim Heng Sim
- Hospital Sungai Buloh
- Winai Ratanasuwan
- Faculty of Medicine, Siriraj Hospital, Mahidol University
- Penh Sun Ly
- National Center for HIV/AIDS, Dermatology & STDs, University of Health Sciences
- Evy Yunihastuti
- Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital
- Sanjay Pujari
- Institute of Infectious Diseases
- Jeremy L. Ross
- TREAT Asia, amfAR, The Foundation for AIDS Research
- Matthew Law
- The Kirby Institute, University of New South Wales
- Somnuek Sungkanuparph
- Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University
- on behalf of the TREAT Asia HIV Observational Databases (TAHOD)
- DOI
- https://doi.org/10.1186/s12981-017-0151-1
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 8
Abstract
Abstract Background Abacavir and rilpivirine are alternative antiretroviral drugs for treatment-naïve HIV-infected patients. However, both drugs are only recommended for the patients who have pre-treatment HIV RNA 30 kg/m2 (OR 2.4 vs. 350 cells/mm3 (OR 3.9 vs. 2000 cells/mm3 (OR 1.7 vs. 25 yielded the sensitivity of 46.7%, specificity of 79.1%, positive predictive value of 67.7%, and negative predictive value of 61.2% for prediction of pre-treatment HIV RNA <100,000 copies/mL among derivation patients. Conclusion A model prediction for pre-treatment HIV RNA <100,000 copies/mL produced an area under the ROC curve of 0.70. A larger sample size for prediction model development as well as for model validation is warranted.
Keywords
